A new study indicates that COVID-19 is associated with an elevated risk of a rare disorder, Guillain-Barré syndrome, within six weeks after infection with the virus.

Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the ...

Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the ...

Since the disorder normally affects about one person in 100,000, this results in an additional 1.6 cases of Guillain-Barré syndrome per one million people vaccinated — still a small risk.

FDA conducted a postmarketing observational study that assessed the risk of GBS following vaccination with the two companies' RSV prefusion F protein vaccines using Medicare claims data from May ...

T he new vaccines that protect older adults against respiratory syncytial virus, or RSV, may be linked to a small increased risk of developing Guillain-Barré syndrome, new data from the Centers ...

Findings from this self-controlled case series showed an increased risk of GBS during the 42 days following vaccination with Abrysvo (9 excess cases per million doses; incidence rate ratio [GBS ...

Guillain-Barre Syndrome (GBS) cases are on the rise in Pune and the nearby areas. According to the latest report, a man suspected to have contracted the condition has died in Maharashtra's Solapur ...

Reports of Guillain-Barré syndrome (GBS) following respiratory syncytial virus (RSV) vaccination in adults ages 60 and up were higher than expected, but the vaccine's benefits still outweigh any ...

Guillain-Barré syndrome (pronounced gee-YAH-buh-RAY) is a rare autoimmune disorder that has been getting attention recently because of its potential connection with the coronavirus. In a letter ...

Guillain-Barré syndrome (GBS) is an acute inflammatory neuropathy that can lead to severe weakness of the limbs, face, and respiratory muscles. Its pathophysiology involves autoantibodies that ...

Abrysvo and Arexvy labels will caution about risk of rare neurologic disorder. advertisement. Medpage Today. FDA Adds Guillain-Barre Syndrome Warning to Two RSV Vaccines. Story by Judy George ...